Literature DB >> 22688440

Palliative treatment of colorectal cancer in Germany: cost of care and quality of life.

Martin Emmert1, Katharina Pohl-Dernick, Axel Wein, Frank Dörje, Susanne Merkel, Frank Boxberger, Gudrun Männlein, Robert Joost, Hans-Detlev Harich, Roland Thiemann, Christof Lamberti, Markus F Neurath, Werner Hohenberger, Oliver Schöffski.   

Abstract

INTRODUCTION: To estimate the costs of palliative care for colorectal cancer (CRC) from the perspective of German statutory health insurance and to measure the patients' quality of life (QoL) for a 2-year time period.
METHODS: A prospective observational multicentre study was carried out to estimate the direct costs of care over a 2-year period. Case report forms, medical records, and claims data were all applied to document medical and resource usage data in real-world settings. QoL was measured by using the Short Form-12 Health Survey.
RESULTS: In total 101 patients (mean age 67.09 ± 11.13 years, 68 % male) from 12 different settings were included. The mean costs per patient during the 1st and 2nd years were calculated to be 42,361€ and 32,023€, respectively. Highest mean costs were calculated for the second quarter, which reached an amount of 12,900€ (95 % CI: 11,127€-14,673€). Mean physical summary scores and mean mental summary scores were 41.8 and 49.7, respectively. DISCUSSION: This is the first study assessing the costs of palliative care and the quality of life of patients with CRC in real-world health-care delivery in Germany. It could be shown that CRC treatment represents an enormous economic burden to the German health-care system. Increased efforts in promoting effective and efficient treatment options, or performance-based medication reimbursement schemes, might be helpful in reducing the costs.

Entities:  

Mesh:

Year:  2012        PMID: 22688440     DOI: 10.1007/s10198-012-0408-5

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  39 in total

1.  Pay-for-performance as a method to establish the business case for quality.

Authors:  John R C Wheeler; Bert White; Simone Rauscher; Tammie A Nahra; Kristin L Reiter; Kathleen M Curtin; Cheryl L Damberg
Journal:  J Health Care Finance       Date:  2007

Review 2.  [Update S3-guideline "colorectal cancer" 2008].

Authors:  W Schmiegel; A Reinacher-Schick; D Arnold; U Graeven; V Heinemann; R Porschen; J Riemann; C Rödel; R Sauer; M Wieser; W Schmitt; H-J Schmoll; T Seufferlein; I Kopp; C Pox
Journal:  Z Gastroenterol       Date:  2008-08       Impact factor: 2.000

3.  The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.

Authors:  S Lopatriello; D Amoroso; S Donati; O Alabiso; L Forti; A Fornasiero; A Smergo; A Lalli; C Iacono; A Lucenti; L D'Alonzo; C Negrini
Journal:  Eur J Cancer       Date:  2008-09-18       Impact factor: 9.162

Review 4.  Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

Authors:  Josh J Carlson; Sean D Sullivan; Louis P Garrison; Peter J Neumann; David L Veenstra
Journal:  Health Policy       Date:  2010-03-11       Impact factor: 2.980

5.  Quality of life after curative liver resection: a single center analysis.

Authors:  Helge Bruns; Kirsten Krätschmer; Ulf Hinz; Anette Brechtel; Monika Keller; Markus-W Büchler; Peter Schemmer
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

6.  Satisfaction and quality of life: a survey-based assessment in patients with a totally implantable venous port system.

Authors:  S N Nagel; U K M Teichgräber; S Kausche; A Lehmann
Journal:  Eur J Cancer Care (Engl)       Date:  2011-08-18       Impact factor: 2.520

7.  Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.

Authors:  M Görner; P Riemer-Hommel
Journal:  Z Gastroenterol       Date:  2008-07       Impact factor: 2.000

8.  Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.

Authors:  A Wein; C Riedel; W Brückl; S Merkel; R Ott; B Hanke; U Baum; F Fuchs; K Günther; T Reck; T Papadopoulos; E G Hahn; W Hohenberger
Journal:  Oncology       Date:  2003       Impact factor: 2.935

9.  Health status of the advanced elderly in six European countries: results from a representative survey using EQ-5D and SF-12.

Authors:  Hans-Helmut König; Dirk Heider; Thomas Lehnert; Steffi G Riedel-Heller; Matthias C Angermeyer; Herbert Matschinger; Gemma Vilagut; Ronny Bruffaerts; Josep M Haro; Giovanni de Girolamo; Ron de Graaf; Viviane Kovess; Jordi Alonso
Journal:  Health Qual Life Outcomes       Date:  2010-11-29       Impact factor: 3.186

10.  Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.

Authors:  D J Watkins; I Chau; D Cunningham; S S Mudan; N Karanjia; G Brown; S Ashley; A R Norman; A Gillbanks
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more
  6 in total

Review 1.  Targeted nanoparticles for colorectal cancer.

Authors:  Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos
Journal:  Nanomedicine (Lond)       Date:  2016-08-16       Impact factor: 5.307

2.  Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.

Authors:  Sonja Koch; Axel Wein; Jürgen Siebler; Frank Boxberger; Markus F Neurath; Hanns-Detlev Harich; Werner Hohenberger; Frank Dörje
Journal:  Support Care Cancer       Date:  2013-04-09       Impact factor: 3.603

3.  Financial burden of colorectal cancer treatment among patients and their families in a middle-income country.

Authors:  Meram Azzani; April Camilla Roslani; Tin Tin Su
Journal:  Support Care Cancer       Date:  2016-05-26       Impact factor: 3.603

4.  Management and intensity of medical end-of-life care in people with colorectal cancer during the year before their death in 2015: A French national observational study.

Authors:  Audrey Tanguy-Melac; Anne-Sophie Aguade; Anne Fagot-Campagna; Christelle Gastaldi-Ménager; Jean-Marc Sabaté; Philippe Tuppin
Journal:  Cancer Med       Date:  2019-09-25       Impact factor: 4.452

5.  Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry.

Authors:  Kathrin Borchert; Christian Jacob; Natalie Wetzel; Martina Jänicke; Egbert Eggers; Annette Sauer; Norbert Marschner; Julia Altevers; Thomas Mittendorf; Wolfgang Greiner
Journal:  Health Econ Rev       Date:  2020-12-12

6.  Effectiveness of two types of palliative home care in cancer and non-cancer patients: A retrospective population-based study using claims data.

Authors:  Markus Krause; Bianka Ditscheid; Thomas Lehmann; Maximiliane Jansky; Ursula Marschall; Winfried Meißner; Friedemann Nauck; Ulrich Wedding; Antje Freytag
Journal:  Palliat Med       Date:  2021-06       Impact factor: 4.762

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.